Combination of Atezolizumab and Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results From a Phase Ib Study - ScienceDirect
Tazverik (tazemetostat) for the Treatment of Epithelioid Sarcoma
Tazemetostat: First Approval | SpringerLink
Tazemetostat for Endometrial Cancer Clinical Trial 2023 | Power
Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma
Targeting Enhancer of Zeste Homolog 2 for the Treatment of Hematological Malignancies and Solid Tumors: Candidate Structure–Activity Relationships Insights and Evolution Prospects | Journal of Medicinal Chemistry
Additional data from Phase 1 study of tazemetostat announced
Histone-writer cancer drugs enter center stage | Nature Biotechnology
Tazemetostat treatment inhibits growth of synovial sarcoma... | Download Scientific Diagram
Current clinical trials for EZH2 inhibitors. | Download Table
Finding an easy way to harmonize: a review of advances in clinical research and combination strategies of EZH2 inhibitors | Clinical Epigenetics | Full Text
FDA Approves Tazemetostat for Advanced Epithelioid Sarcoma | ONS Voice
ESMO 2021: Safety of Tazemetostat in Combination With Abiraterone/Prednisone or Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
Cancers | Free Full-Text | Evaluation of Tazemetostat as a Therapeutically Relevant Substance in Biliary Tract Cancer
Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK™ (tazemetostat) for the Treatment of Patients with Epithelioid Sarcoma | Business Wire
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study - The Lancet Oncology
tazemetostat | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study - The Lancet Oncology
Known EZH2 inhibitors. GSK126, tazemetostat and CPI-1205 are in... | Download Scientific Diagram
Tazemetostat - Wikipedia
Buy Tazverik (tazemetostat) Online • Price & Costs | Everyone.org
ANTICANCER AGENT “TAZVERIK® TABLETS 200mg” (TAZEMETOSTAT HYDROBROMIDE) LAUNCHED IN JAPAN FOR EZH2 GENE MUTATION-POSITIVE FOLLICULAR LYMPHOMA | News Release：2021 | Eisai Co., Ltd.
EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study - The Lancet Oncology
Discovery of a Novel Covalent EZH2 Inhibitor Based on Tazemetostat Scaffold for the Treatment of Ovarian Cancer | Journal of Medicinal Chemistry
Tazemetostat Is Associated with Lower Risk for Safety Outcomes Versus the PI3-Kinases Idelalisib, Duvelisib and Copanlisib, in Patients with Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 2 Prior Systemic Treatments: A
Epizyme Announces the U.S. Food and Drug Administration Lifts Partial Clinical Hold on Tazemetostat Clinical Program | Business Wire
Cancers | Free Full-Text | Evaluation of Tazemetostat as a Therapeutically Relevant Substance in Biliary Tract Cancer
Cancers | Free Full-Text | Evaluation of Tazemetostat as a Therapeutically Relevant Substance in Biliary Tract Cancer
